Part I: IPR & Insulin – The True Value of PTAB Proceedings Year after year, pharmaceutical companies engage in anticompetitive strategies to game the U.S. patent system and keep drug prices high at the expense of patients. Even as millions of Americans grapple with financial hardships brought on by the COVID-19 pandemic, these pharmaceutical companies […]

Continue Reading

Patients Face Rising Costs for Critical Medications to Treat COVID-19 Related Effects WASHINGTON D.C. – Even before the COVID-19 pandemic, more than 58 million Americans struggled to afford their prescription drugs.  Now, the economic impact of the health crisis continues to leave millions of American workers, families and seniors struggling just to stay afloat.  Meanwhile, a new report released by Patients For […]

Continue Reading

WASHINGTON D.C. – As millions of Americans continue to grapple with high drug prices, a case before the U.S. Supreme Court surrounding the constitutionality of the Patent Trial and Appeal Board (PTAB) has taken on national significance for this growing national problem.  That’s why the Coalition Against Patent Abuse (CAPA) last week filed an amicus brief with […]

Continue Reading

WASHINGTON D.C. – As part of its ongoing campaign to safeguard the U.S. patent system and stop Big Pharma from gaming the system, the Coalition Against Patent Abuse (CAPA) this week filed comments with the United States Patent and Trademark Office (USPTO) outlining its concerns regarding the increased use of discretionary denials by the Patent Trial and Appeal […]

Continue Reading

Broad, Bipartisan Support Exists for Congress to Pass Drug Pricing Reforms Next Year and Reform the Patent System WASHINGTON D.C. – A new post-election survey of almost 2,000 registered voters nationwide conducted by Morning Consult finds that the rising cost of prescription drugs was a top issue for voters in this year’s election and moving forward […]

Continue Reading

Polls Show Rising Cost of Drugs Is One Of The Most Important Issues To U.S. Voters WASHINGTON, D.C. – The Coalition Against Patent Abuse (CAPA) – a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others – released a memo to the two major Presidential campaigns and Members of Congress today encouraging Washington […]

Continue Reading

The 2020 Access & Savings Report Reinforces The Importance Of Reforming Our U.S. Healthcare System To Increase Competition, Save Billions IN CASE YOU MISSED IT: This week, the Association for Accessible Medicines (AAM) – a member of the Coalition Against Patent Abuse (CAPA) – released their annual report on generic drug and biosimilars access and […]

Continue Reading

WASHINGTON, D.C. – The Coalition Against Patent Abuse (CAPA), a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others, issued a statement today supporting a new study entitled, “The Growing Power of Biotech Monopolies Threatens Affordable Care” by Avik Roy and Gregg Girvan of the Foundation for Research on Equal Opportunity (FREOPP) which […]

Continue Reading

IN CASE YOU MISSED IT: A new study by Alex Brill of Matrix Global Advisors (MGA) and commissioned by the Coalition for Affordable Prescription Drugs (CAPD) offers the latest evidence that pharma’s delay tactics are costing Americans billions of dollars. These challenges are especially important as the federal government faces unprecedented debt and millions of Americans are […]

Continue Reading

WASHINGTON, D.C. – The Coalition Against Patent Abuse (CAPA), a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others, applauded a decision today by the U.S. House of Representatives’ Committee on Oversight and Reform to subpoena AbbVie, the drug company that makes Humira, as part of its probe into pricing […]

Continue Reading